Advertisement

Supportive Care in Cancer

, Volume 26, Issue 9, pp 3055–3061 | Cite as

Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma

  • J. M. Sivik
  • J. Davidson
  • C. M. Hale
  • J. J. Drabick
  • G. Talamo
Original Article

Abstract

Background

The most commonly used antibacterial prophylaxis during autologous stem cell transplants (ASCT) for multiple myeloma (MM) involves a fluoroquinolone, such as ciprofloxacin or levofloxacin. We assessed the impact of adding doxycycline to ciprofloxacin as routine antibacterial prophylaxis in these patients.

Methods

We retrospectively reviewed electronic medical records and our ASCT database to analyze rates and types of bacterial infections in MM patients who underwent ASCT in our institution.

Results

Among 419 patients, 118 received ciprofloxacin alone (cipro group), and 301 ciprofloxacin and doxycycline (cipro-doxy group). Neutropenic fever (NF) developed in 63 (53%) and 108 (36%) patients of the cipro and cipro-doxy groups, respectively (p = 0.010). The number of documented bacteremic episodes was 13 (11%) and 14 (4.7%) in the two groups, respectively (p = 0.017). Antimicrobial resistance and Clostridium difficile infections were uncommon. Transplant-related mortality was 1% in both groups.

Conclusions

The addition of doxycycline to standard prophylaxis with ciprofloxacin seems to reduce the number of NF episodes and documented bacterial infections in patients with MM undergoing ASCT, without increasing rate of serious complications.

Keywords

Doxycycline High-dose melphalan Autologous stem cell transplant Infection prophylaxis Multiple myeloma 

Notes

Author contributions

Jeffrey M. Sivik, PharmD: primary/corresponding author—responsible for drafting article, concept/design, data analysis/interpretation, critical revision of article, and final approval of article

Jo Ann Davidson, CRNP: responsible for data collection/analysis/interpretation, critical revision of article, and approval of article

Cory M. Hale, PharmD: responsible for data analysis/interpretation, critical revision of article, and approval of article

Joseph J. Drabick, MD: responsible for data analysis/interpretation, critical revision of article, and approval of article

Giampaolo Talamo, MD: senior author, responsible for concept/design, statistics, data collection/analysis/interpretation, critical revision of article, and approval of article

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT (2005) Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council adult leukemia working party. J Clin Oncol 23:9219–9226CrossRefPubMedGoogle Scholar
  2. 2.
    Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 49:1211–1225CrossRefPubMedGoogle Scholar
  3. 3.
    Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA (2015) Risks, severity and timing of infections with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 171:100–108CrossRefPubMedGoogle Scholar
  4. 4.
    Valkovic T, Gacic V, Ivandic J, Petrov B, Dobrila-Dintinjana R et al (2015) Infections in hospitalized patients with multiple myeloma: main characteristics and risk factors. Turk J Hematol 32:234–242CrossRefGoogle Scholar
  5. 5.
    Palumbo A, Cavallo F, Gay F, Di Raimondo F, Yehuda DB, Petrucci MT et al (2014) Autologous transplantation and maintenance therapy in multiple myeloma. New Engl J Med 371:895–905CrossRefPubMedGoogle Scholar
  6. 6.
    Voorhees PM, Usmani SZ (2016) The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. Clin Adv Hematol Oncol 14:719–728PubMedGoogle Scholar
  7. 7.
    Afessa B, Peters SG (2006) Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med 27:297–309CrossRefPubMedGoogle Scholar
  8. 8.
    Magauran CE, Salgado CD (2011) Challenges and advances in infection control of hematopoietic stem cell transplant recipients. Infect Disord Drug Targets 11:18–26CrossRefPubMedGoogle Scholar
  9. 9.
    Salzman MB, Rubin LG (1995) Intravenous catheter-related infections. Adv Pediatr Infect Dis 10:337–368PubMedGoogle Scholar
  10. 10.
    Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, Raad II, Rijnders BJA, Sherertz RJ, Warren DK (2009) Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 updates by the Infectious Diseases Society of America. Clin Infect Dis 49:1–45CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE, Walsh TJ, Gergis U (2015) Impact of prophylactic levofloxacin on rates of bloodstream infection and fever in neutropenic patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. BIol Blood Marrow Transplant 21:1808–1814CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Parmar SR, Bookout R, Shapiro JF, Tombleson R, Perkins J, Kim J, Yue B, Tomblyn M, Alsina M, Nishihori T (2014) Comparison of 1-day vs 2-day dosing of high dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Bone Marrow Transplant 49:761–766CrossRefPubMedGoogle Scholar
  13. 13.
    St Bernard R, Chodirker L, Masih-Khan E, Jiang H, Franke N, Kukreti V, Tiedemann R, Trudel S, Reece D, Chen CI (2015) Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant 50:95–99CrossRefPubMedGoogle Scholar
  14. 14.
    Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, del Favero A, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New Engl J Med. 353:977–987CrossRefPubMedGoogle Scholar
  15. 15.
    Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995CrossRefPubMedGoogle Scholar
  16. 16.
    Freifield AG, Bow EJ, Sepkowicz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56–e93CrossRefGoogle Scholar
  17. 17.
    Saini L, Rostein C, Atenafu EG, Brandwein JM (2013) Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant E. coli. BMC Infect Dis 13:284CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Baydoun M, Otrock ZK, Okaily S, Nehme R, Abu-Chahine R, Hamdan A, Noureddine S, Kanj S, Kanafani Z, Bazarbachi A, Kharfan-Dabaja MA (2013) Prophylactic administration of doxycycline reduces central venous catheter infections in patients undergoing hematopoietic cell transplantation. Mediterr J Hematol Infect Dis 5(1):e2013015CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Talamo G, Claxton DF, Dougherty DW, Ehmann CW, Sivik J, Drabick JJ, Rybka W (2009) BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Bone Marrow Transplant 44:157–161CrossRefPubMedGoogle Scholar
  20. 20.
    Talamo G, Rakszawski KL, Rybka WB, Dolloff NG, Malysz J, Berno T, Zangari M (2012) Effect of time to infusion of autologous stem cells (24 vs 48 h) after high-dose melphalan in patients with multiple myeloma. Eur J Hematol 89:145–150CrossRefGoogle Scholar
  21. 21.
    Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH (2015) BEAM conditioning regimen has higher toxicity compared with high-dose melphalan for salvage autologous hematopoietic stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma Leuk 15:531–535CrossRefPubMedGoogle Scholar
  22. 22.
    Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 13:588–595CrossRefPubMedGoogle Scholar
  23. 23.
    Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473CrossRefPubMedGoogle Scholar
  24. 24.
    Trifilo S, Verma A, Mehta J (2004) Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 33:735–739CrossRefGoogle Scholar
  25. 25.
    Reuter S, Kern WV, Sigge A, Dohner H, Marre R, Kern P, von Baum H (2005) Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 40:1087–1093CrossRefPubMedGoogle Scholar
  26. 26.
    Wong JR, Bauer KA, Mangino JE, Goff DA (2012) Antimicrobial stewardship pharmacist interventions for coagulase-negative staphylococci positive blood cultures using rapid polymerase chain reaction. Ann Pharmacother 46:1484–1490CrossRefPubMedGoogle Scholar
  27. 27.
    Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA, Weinstein RA, Sepkowitz KA, Jernigan JA, Sanogo K, Wong ES (2013) Effect of daily chlorhexidine bathing on hospital-acquired infection. New Engl J Med. 368:533–542CrossRefPubMedGoogle Scholar
  28. 28.
    Doernberg SB, Winston LG, Deck DH, Chambers HF (2012) Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis 55:615–620CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Sferra TJ, Hernandez AV (2013) Donskey CJ. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 68:1951–1961CrossRefPubMedGoogle Scholar
  30. 30.
    Tariq R, Cho J, Kapoor S, Orenstein R, Singh S, Pardi DS, Khanna S (2018) Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis. Clin Infect Dis 66:514–522CrossRefPubMedGoogle Scholar
  31. 31.
    Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C et al (2001) Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 98:2059–2064CrossRefPubMedGoogle Scholar
  32. 32.
    Park H, Youk J, Kim HR, Koh Y, Kwon JH, Yoon SS, Park S, Choe PG, Kim NJ, Oh MD, Park WB, Kim I (2017) Infectious complications in multiple myeloma receiving autologous stem cell transplantation in the past 10 years. Int J Hematol 106:801–810.  https://doi.org/10.1007/s12185-017-2313-2 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PharmacyPenn State Health—M.S. Hershey Medical CenterHersheyUSA
  2. 2.Department of Medicine, Hematology/Oncology DivisionPenn State College of MedicineHersheyUSA

Personalised recommendations